Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

HEALTH SERVICES AND OUTCOMES

RESEARCH LETTER

REVIEW ARTICLE

CLINICAL TRIALS AND OBSERVATIONS

T cell exhaustion and an immunosuppressive microenvironment is a hallmark of CTCL. Durvalumab combined with lenalidomide has the potential to enhance anti-tumor immunity in CTCL.

THROMBOSIS AND HEMOSTASIS

Red Cells, Iron, and Erythropoiesis

SYSTEMATIC REVIEW

MYELOID NEOPLASIA

Inside Blood Advances

Lymphoid Neoplasia

REGULAR ARTICLE

TRANSPLANTATION

Hematopoiesis and Stem Cells

ERRATUM

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals